Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Marnetta Bradford

Nurse Practitioner Hanover Township, PA Nurse Practitioner

NPI 1811000821 CMS profile 10909615

101 W End Rd 18706, Hanover Township, PA 18706

Open in the dashboard

General payments

$9,355

687 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Marnetta Bradford of Hanover Township, PA is reported in the CMS Open Payments database as having received $9,355 across 687 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $74 4
2023 General $2,247 152
2022 General $3,439 250
2021 General $3,596 281

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marnetta Bradford
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Marnetta Bradford were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Marnetta Bradford Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $3,596 $135 $40–$426 $132
2022 $3,439 $152 $48–$470 $149
2023 $2,247 $166 $54–$529 $160
2024 $74 $173 $55–$556 $164
2025 $0 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Novo Nordisk Inc $1,430 149 payments
  2. Amgen Inc. $992 68 payments
  3. AbbVie, Inc. $977 64 payments
  4. Pfizer Inc. $791 51 payments
  5. Janssen Pharmaceuticals, Inc $758 64 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $577 31 payments
  7. AstraZeneca Pharmaceuticals LP $571 32 payments
  8. Lilly USA, LLC $438 35 payments
  9. Astellas Pharma US Inc $300 22 payments
  10. Kowa Pharmaceuticals America, Inc. $272 19 payments
  11. Other $2,250 152 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $9,355 687 payments
Products named General payments · program years 2021–2024
  1. Ozempic $1,219 131 payments
  2. RYBELSUS $1,207 130 payments
  3. Repatha $799 59 payments
  4. Otezla $784 53 payments
  5. XARELTO $640 57 payments
  6. FARXIGA $372 17 payments
  7. VRAYLAR $339 25 payments
  8. PREVNAR 20 $332 16 payments
  9. BREZTRI $317 14 payments
  10. UBRELVY $295 19 payments
  11. Other $7,667 515 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

615

Median for Nurse Practitioner: 389

Drug cost

$29,073

Median for Nurse Practitioner: $21,885

Branded share of claims

17.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 16 $12,258
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 13 $9,969
Albuterol Sulfate Hfa Albuterol Sulfate Brand 29 $831
Diclofenac Sodium Generic 13 $638
Omeprazole Generic 45 $457
Metoprolol Succinate Generic 36 $433
Atorvastatin Calcium Generic 42 $400
Gabapentin Generic 14 $361
Pravastatin Sodium Generic 23 $350
Diltiazem 24hr Er Diltiazem Hcl Brand 14 $338

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ABRYSVO
  • PFIZER INC. $14
$14 — —
Veozah
  • Astellas Pharma US Inc $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

687 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record